PDF(Pubmed)
Abstract：
As an immune-response modifier, imiquimod can bind to Toll-like receptors on immune cells and enhance innate and adaptive immune responses, exerting potential antitumor and antiviral effects, which led to its approval by the US Food and Drug Administration for the treatment of actinic keratosis, superficial basal cell carcinomas, and anogenital warts, and to its off-label use in treating many other benign and malignant dermatoses. Although topical administration of imiquimod has been considered well tolerated, an increasing number of cutaneous and noncutaneous side effects are being reported as its clinical applications expand. This review primarily focuses on rare cutaneous side effects. To the best of our knowledge, this is the first article to summarize the mechanism, diagnosis, and management of rare cutaneous side effects of imiquimod, which may help to heighten awareness among physicians, especially dermatologists, about potential imiquimod-induced cutaneous side effects.
摘要：
作为免疫反应调节剂，咪喹莫特可与免疫细胞上的Toll样受体结合，增强先天和适应性免疫反应，发挥潜在的抗肿瘤和抗病毒作用，这导致其被美国食品和药物管理局批准用于治疗光化性角化病，浅表基底细胞癌，和肛门生殖器疣,以及其在治疗许多其他良性和恶性皮肤病中的标签外使用。尽管咪喹莫特的局部给药被认为具有良好的耐受性，随着临床应用的扩大，越来越多的皮肤和非皮肤副作用被报道。这篇综述主要集中在罕见的皮肤副作用。据我们所知,这是第一篇总结机制的文章，诊断,以及咪喹莫特罕见皮肤副作用的管理，这可能有助于提高医生的意识，尤其是皮肤科医生,关于潜在的咪喹莫特引起的皮肤副作用。
